Hemostemix Inc. (CVE:HEM – Get Free Report) hit a new 52-week low on Friday. The company traded as low as C$0.05 and last traded at C$0.05, with a volume of 99,539 shares. The stock had previously closed at C$0.06.
Hemostemix Price Performance
The company has a current ratio of 0.13, a quick ratio of 0.48 and a debt-to-equity ratio of -61.85. The stock has a market capitalization of C$10.57 million, a P/E ratio of -1.92 and a beta of -0.14. The company has a fifty day simple moving average of C$0.06 and a two-hundred day simple moving average of C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Read More
- Five stocks we like better than Hemostemix
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
